Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 3, 2008 Brian Lawler	A Cubist Masterstroke Cubist Pharmaceuticals, until now a one-drug wonder, becomes a marketer of two compounds.
The Motley Fool July 20, 2006 Brian Lawler	Cubist's Square Results The pharmaceutical company has a promising new drug, but little else in the pipeline. Investors, take note.
The Motley Fool October 20, 2006 Brian Lawler	Cubist Paints a Greener Picture The pharmaceutical company is flush with cash and finally profitable. However, it might just be easier for Cubist to sell itself to a more substantial pharmaceutical company. Investors, take note.
The Motley Fool May 12, 2004 Charly Travers	Cubist Addresses a Niche Market This small firm is developing antibiotics to meet a medical need.
The Motley Fool October 20, 2011 Travis Hoium	Cubist Pharmaceuticals Shares Popped: What You Need to Know Shares of Cubist Pharmaceuticals jumped 10% today after the company released earnings.
The Motley Fool January 29, 2007 Brian Lawler	No Dicey Results for Cubist The stock price may be down, but Cubist Pharmaceuticals is looking strong.
The Motley Fool January 26, 2005 Charly Travers	Call Cubist in the Morning Strong drug sales provide a dose of good medicine for this pharmaceutical.
The Motley Fool April 5, 2011 Cindy Johnson	Cubist Pharmaceuticals Shares Popped: What You Need to Know Cubist Pharmaceuticals popped as much as 17% in intraday trading today after announcing a licensing agreement and the settlement of a patent dispute.
The Motley Fool April 5, 2011 Brian Orelli	Suit Settlement Sends Shares Skyrocketing Cubist Pharmaceuticals gets concessions as it settles its patent suit with Teva.
The Motley Fool October 27, 2004 Charly Travers	Cubist's Growing Pains The pharmaceutical is going to have to work through some growing pains and make strides toward profitability before the performance of the stock will match the performance of its drug.
The Motley Fool April 6, 2011 Brian Orelli	Killing Bacteria With the Help of a Friend Optimer Pharmaceuticals has signed up Cubist Pharmaceuticals as a marketing partner for at least the next two years.
The Motley Fool June 28, 2005 Charly Travers	Growth Around the Corner? Despite a thin pipeline, small biotech Cubist Pharmaceuticals is hoping to ride the wave of prosperity. Investors, take note.
The Motley Fool April 8, 2005 Brian Gorman	Cubist in Neutral Cubist Pharmaceuticals' pipeline may be why investors are unimpressed.
The Motley Fool December 28, 2007 Brian Lawler	Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.
The Motley Fool January 9, 2009 Brian Orelli	Alnylam Holds Hands With a New Fella Is big pharma turning up its nose at RNAi drugs?
The Motley Fool July 11, 2011	Cubist Pharmaceuticals Earnings Preview Cubist Pharmaceuticals will unveil its latest earnings on Thursday.
Chemistry World December 11, 2014	Merck to buy antibiotics specialist Cubist Hours after the deal was announced, a US District Court invalidated several key patents for Cubist's top seller, Cubicin (daptomycin).
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
The Motley Fool February 29, 2008 Brian Orelli	Merck's Complicated Partnerships Merck has decided to continue its complicated partnership with AstraZeneca for at least a few more years.
The Motley Fool August 31, 2010 Brian Orelli	A Mostly Meaningless FDA Rejection The Food and Drug Administration sends AstraZeneca back to the drawing board for the second time when it rejected motavizumab, the drugmaker's newest treatment for respiratory syncytial virus.
The Motley Fool May 25, 2011 David Williamson	Pay Attention to Shire The British ADHD medicine maker is busy making big moves.
The Motley Fool December 28, 2005 Stephen D. Simpson	AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either.
Pharmaceutical Executive October 1, 2008 Michael Bonney	Specialty Sales Gets No Resistance The author, a Cubist Pharmaceuticals CEO. has given his company a successful start and is now predicting the future of drug resistance.
The Motley Fool August 3, 2006 S.J. Caplan	AstraZeneca's Path to Avoid Pain The pharmaceutical giant partners with Pozen to co-develop a drug. Take heart, AstraZeneca shareholders! No queasy stomachs are expected in your future.
The Motley Fool October 26, 2006 Brian Lawler	Market Rejects AstraZeneca's Remedy Investors pummel the pharmaceutical firm, despite its impressive results.
BusinessWeek June 2, 2011 Kresge & Connolly	A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies.
The Motley Fool October 14, 2010 Sean Williams	Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away.
The Motley Fool July 27, 2006 Stephen D. Simpson	AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain.
BusinessWeek December 29, 2010 Kelley & Cortez	AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs.
The Motley Fool January 13, 2004 David Nierengarten	Vicuron's Booster Shot With a new "super-tough" antibiotic, Vicuron's stock is super high.
The Motley Fool January 28, 2011 Alan Oscroft	AstraZeneca to Double Buybacks Regulatory setbacks have hit the drug firm's profits, but things look pretty resilient overall.
Chemistry World July 15, 2010 Matt Wilkinson	Biotechs plot path of least resistance Biopharmaceutical companies are moving into antibiotics, and filling the void left by big pharma.
The Motley Fool July 30, 2010 Cliff D'Arcy	Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline.
The Motley Fool August 20, 2011 Rex Moore	2 Positive Signs for Cubist Pharmaceuticals Cubist Pharmaceuticals appears to be in good shape in terms of the intangible assets ratio and tangible book value.
The Motley Fool September 30, 2011 David Williamson	This Week in Biotech Biotech news about Array BioPharma, Human Genome Sciences, Pharmasset, and more.
The Motley Fool February 5, 2007 Billy Fisher	A Fresh Outlook at AstraZeneca Strong performance makes management happy at the European drug giant. As long as the company is able to continue the strong revenue growth from its major contributors, shareholders will be able to enjoy a prosperous 2007.
BusinessWeek October 29, 2007 Catherine Arnst	Superbugs: Where Are the Wonder Drugs? Antibiotics are losing the battle against superbugs, and drugmakers are slow to replenish the arsenal.
The Motley Fool November 15, 2011 Selena Maranjian	Make Money in Profitable Small Caps the Easy Way If you expect small companies to do well in coming years as the global economy recovers, the iShares S&P SmallCap 600 Index ETF could save you a lot of trouble.
The Motley Fool February 2, 2006 Stephen D. Simpson	AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here.
The Motley Fool October 11, 2011 Cliff D'Arcy	AstraZeneca Loves This $100Bn Market The British pharma firm makes its largest-ever manufacturing investment -- in China.
Chemistry World March 11, 2015 Rebecca Trager	Mergers and moves trigger pharma layoffs Downsizing in the pharmaceutical industry is discussed.
The Motley Fool February 1, 2008 Brian Lawler	AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs.
Chemistry World February 2, 2012 Andrew Turley	AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term.
BusinessWeek January 31, 2005 Kerry Capell	No Relief For AstraZeneca More bad news about potential blockbusters weakens Europe's third-largest drugmaker. Analysts say the only thing keeping Astra's shares from going into free fall is the mounting speculation that GSK might make a play for the troubled drugmaker.
The Motley Fool April 30, 2010 Brian Orelli	Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter.
The Motley Fool May 29, 2009 Brian Orelli	The Clouds Are Parting The Food and Drug Administration has scheduled an advisory committee meeting for Aug. 4 to get input on whether the agency should approve generic versions of ViroPharma's antibiotic, Vancocin.
The Motley Fool May 21, 2009 Robert Steyer	The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations?